205 related articles for article (PubMed ID: 18757777)
1. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Dietlein M; Franklin J; Markova J; Lohri A; Amthauer H; Klutmann S; Knapp WH; Zijlstra JM; Bockisch A; Weckesser M; Lorenz R; Schreckenberger M; Bares R; Eich HT; Mueller RP; Fuchs M; Borchmann P; Schicha H; Diehl V; Engert A
Blood; 2008 Nov; 112(10):3989-94. PubMed ID: 18757777
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
Markova J; Kobe C; Skopalova M; Klaskova K; Dedeckova K; Plütschow A; Eich HT; Dietlein M; Engert A; Kozak T
Ann Oncol; 2009 Jul; 20(7):1270-4. PubMed ID: 19228806
[TBL] [Abstract][Full Text] [Related]
3. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
4. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
5. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
6. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
7. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
[TBL] [Abstract][Full Text] [Related]
8. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group.
Kriz J; Reinartz G; Dietlein M; Kobe C; Kuhnert G; Haverkamp H; Haverkamp U; Engenhart-Cabillic R; Herfarth K; Lukas P; Schmidberger H; Staar S; Hegerfeld K; Baues C; Engert A; Eich HT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):46-53. PubMed ID: 25863753
[TBL] [Abstract][Full Text] [Related]
9. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Weihrauch MR; Re D; Scheidhauer K; Ansén S; Dietlein M; Bischoff S; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H
Blood; 2001 Nov; 98(10):2930-4. PubMed ID: 11698273
[TBL] [Abstract][Full Text] [Related]
10. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
[TBL] [Abstract][Full Text] [Related]
11. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
12. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
14. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
15. Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
Bröckelmann PJ; Sasse S; Engert A
Blood; 2018 Apr; 131(15):1666-1678. PubMed ID: 29500174
[TBL] [Abstract][Full Text] [Related]
16. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl S; Goergen H; Buehnen I; Kobe C; Moccia A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P;
Lancet Haematol; 2021 Jun; 8(6):e398-e409. PubMed ID: 34048679
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
18. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
[TBL] [Abstract][Full Text] [Related]
19. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
20. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
